EmblemHealth, a US-based non-profit health insurer, has cut the number of medical procedures for which members will require prior authorisation before receiving care, effective 1 January 2020, it was reported yesterday.
The change affects all of the company's health insurance plans, including Medicaid managed care, Medicare Advantage, coverage provided through employers, and Individual Market plans on the Exchange.
Karen Ignagni, president and CEO of EmblemHealth, said, 'EmblemHealth is transforming all of its operations. As part of that effort, we are reducing red tape and simplifying administrative processes for our clinical partners. This has led us to cut prior authorisation requirements in half. Through careful analysis of our data, we identified services that almost always get approved. Not requiring prior authorisation of those services, such as surgical procedures where patients are going to the hospital (ie some cardiac and vascular procedures, gallbladder removal and treatment of glaucoma), will ensure that our members are receiving the care they need quickly and efficiently. Looking forward, we will continue to review our data with the goal of finding additional ways to reduce red tape and simplify administrative procedures.'
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
American Regent recalls one lot of Papaverine Hydrochloride Injection due to particulate matter
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
EQT to acquire biosurgery company Corza Biosurgery
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy